Compare Stocks: GALT, AVBP, RIGL, and KURA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$21.00 +9.4%	$26.19	$11.36 ▼ $35.83	$1.04B	1.34	2.33 million shs	3.28 million shs
GALT Galectin Therapeutics	$3.19 -5.6%	$3.85	$2.03 ▼ $7.13	$210.08M	0.38	213,151 shs	195,198 shs
KURA Kura Oncology	$9.61 -2.5%	$11.35	$7.36 ▼ $13.90	$854.91M	0.47	1.66 million shs	1.56 million shs
RIGL Rigel Pharmaceuticals	$48.13 -1.5%	$47.15	$24.95 ▼ $52.24	$890.51M	1.19	213,871 shs	119,260 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	+26.05%	-30.23%	-33.82%	+13.57%
GALT Galectin Therapeutics	0.00%	-11.88%	-19.44%	-8.07%	-34.63%
KURA Kura Oncology	0.00%	+5.84%	-11.51%	-7.51%	+3.56%
RIGL Rigel Pharmaceuticals	0.00%	+4.70%	+0.50%	+31.00%	+56.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$21.00 +9.4%	$26.19	$11.36 ▼ $35.83	$1.04B	1.34	2.33 million shs	3.28 million shs
GALT Galectin Therapeutics	$3.19 -5.6%	$3.85	$2.03 ▼ $7.13	$210.08M	0.38	213,151 shs	195,198 shs
KURA Kura Oncology	$9.61 -2.5%	$11.35	$7.36 ▼ $13.90	$854.91M	0.47	1.66 million shs	1.56 million shs
RIGL Rigel Pharmaceuticals	$48.13 -1.5%	$47.15	$24.95 ▼ $52.24	$890.51M	1.19	213,871 shs	119,260 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	+26.05%	-30.23%	-33.82%	+13.57%
GALT Galectin Therapeutics	0.00%	-11.88%	-19.44%	-8.07%	-34.63%
KURA Kura Oncology	0.00%	+5.84%	-11.51%	-7.51%	+3.56%
RIGL Rigel Pharmaceuticals	0.00%	+4.70%	+0.50%	+31.00%	+56.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	2.73	Moderate Buy	$25.67	22.22% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	244.83% Upside
KURA Kura Oncology	2.77	Moderate Buy	$25.35	163.82% Upside
RIGL Rigel Pharmaceuticals	2.43	Hold	$59.00	22.58% Upside

Current Analyst Ratings Breakdown

Latest GALT, AVBP, RIGL, and KURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	AVBP ArriVent BioPharma	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$45.00 ➝ $29.00
10/19/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$85.00
10/16/2026	AVBP ArriVent BioPharma	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$29.00
10/15/2026	AVBP ArriVent BioPharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	KURA Kura Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
10/14/2026	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$24.00
10/14/2026	KURA Kura Oncology	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$24.00
10/14/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/14/2026	RIGL Rigel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/8/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B-) ➝ Buy (B)

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.44 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.99) per share	N/A
KURA Kura Oncology	$67.48M	12.67	N/A	N/A	$2.00 per share	4.81
RIGL Rigel Pharmaceuticals	$294.28M	3.03	$6.74 per share	7.14	$21.57 per share	2.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$166.31M	-$3.62	N/A	N/A	N/A	N/A	-50.26%	-46.66%	11/16/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.95	11.14	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)

Latest GALT, AVBP, RIGL, and KURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/16/2026	Q3 2026	AVBP ArriVent BioPharma	-$1.04	N/A	N/A	N/A	$0.80 million	N/A
11/13/2026	Q3 2026	GALT Galectin Therapeutics	-$0.05	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	KURA Kura Oncology	-$0.8144	N/A	N/A	N/A	$24.86 million	N/A
11/3/2026	Q3 2026	RIGL Rigel Pharmaceuticals	$0.9210	N/A	N/A	N/A	$80.10 million	N/A
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/12/2026	Q2 2026	AVBP ArriVent BioPharma	-$0.9873	-$1.05	-$0.0627	-$1.05	N/A	N/A
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.16	14.16
GALT Galectin Therapeutics	N/A	0.10	0.10
KURA Kura Oncology	0.12	4.73	4.71
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
GALT Galectin Therapeutics	11.68%
KURA Kura Oncology	N/A
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	8.58%
GALT Galectin Therapeutics	53.00%
KURA Kura Oncology	7.60%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	77	49.31 million	45.08 million	Optionable
GALT Galectin Therapeutics	9	65.86 million	30.95 million	Optionable
KURA Kura Oncology	260	88.96 million	82.20 million	Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable

GALT, AVBP, RIGL, and KURA Headlines

Recent News About These Companies

Rigel Pharmaceuticals: Turning Big Pharma's Castoffs Into A Growth Engine

October 22 at 7:31 AM | seekingalpha.com

HC Wainwright Reaffirms "Buy" Rating for Rigel Pharmaceuticals (NASDAQ:RIGL)

October 21, 2026 | americanbankingnews.com

Rigel Pharmaceuticals, Inc. Highlights New GAVRETO® (Pralsetinib) Data Across RET Fusion-Positive Cancers At ESMO Congress 2026

October 20, 2026 | marketscreener.comM

Rigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC Wainwright

October 19, 2026 | marketbeat.com

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

October 19, 2026 | prnewswire.com

Rigel Pharmaceuticals (NASDAQ:RIGL) vs. Ascendis Pharma A/S (NASDAQ:ASND) Head to Head Survey

October 19, 2026 | americanbankingnews.com

535,685 Shares of Rigel Pharmaceuticals, Inc. $RIGL Bought by Assenagon Asset Management S.A.

October 19, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Bumped Down to "Strong Sell" by Zacks Research

October 16, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock Has Consensus Target Price of $59.00 According to Analysts

October 15, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Price Breaks Above 200-Day Moving Average - Here's Why

October 10, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 2, 2026 | prnewswire.com

RIGL.OQ - | Stock Price & Latest News | Reuters

October 1, 2026 | reuters.com

Bank of America Corp DE Purchases 123,506 Shares of Rigel Pharmaceuticals, Inc. $RIGL

September 29, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference - Slideshow

September 15, 2026 | seekingalpha.com

Rigel Pharmaceuticals op H.C. Wainwright-conferentie: groeiplan verbreed

September 15, 2026 | nl.investing.com

Rigel Pharmaceuticals, Inc. (RIGL) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow

September 15, 2026 | seekingalpha.com

Rigel to Participate in Upcoming September Investor Conferences

September 2, 2026 | prnewswire.com

Rigel Pharmaceuticals

August 17, 2026 | money.usnews.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13, 2026 | prnewswire.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, AVBP, RIGL, and KURA Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$21.00 +1.80 (+9.38%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$20.89 -0.11 (-0.52%)

As of 10/23/2026 07:53 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Galectin Therapeutics NASDAQ:GALT

$3.19 -0.19 (-5.62%)

As of 10/23/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Kura Oncology NASDAQ:KURA

$9.61 -0.25 (-2.54%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$9.56 -0.04 (-0.47%)

As of 10/23/2026 07:30 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$48.13 -0.73 (-1.49%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$48.17 +0.04 (+0.08%)

As of 10/23/2026 07:30 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, AVBP, RIGL, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, AVBP, RIGL, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, AVBP, RIGL, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, AVBP, RIGL, and KURA Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

Galectin Therapeutics NASDAQ:GALT

Kura Oncology NASDAQ:KURA

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, AVBP, RIGL, and KURA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, AVBP, RIGL, and KURA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, AVBP, RIGL, and KURA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, AVBP, RIGL, and KURA Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

Galectin Therapeutics NASDAQ:GALT

Kura Oncology NASDAQ:KURA

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools